As leaders within the science of obesity, we are working to make obesity a healthcare priority, defeat stigma and support better access to evidence-based care. Scientific and medical experts are increasingly recognising obesity as a serious chronic disease.

As leaders in the science of obesity, we are working to make obesity a healthcare priority, defeat stigma and support better access to evidence-based care. We aim to be the leading force in the science behind obesity. Learn more about our ambitious R&D pipeline.

We are on a mission to increase awareness about obesity and its causes, destigmatise this chronic disease, and provide diverse treatment options. We are working towards a future where we can help prevent and treat obesity – and even ultimately cure it.

As leaders within the science of obesity, Novo Nordisk established the Transformational Prevention Unit (TPU) to tackle one of the world’s foremost health challenges and drive change within obesity prevention.

At Novo Nordisk, we are dedicated to making obesity a healthcare priority. We are committed to helping improve the lives of people with obesity by changing how the world sees, prevents and treats obesity.

2 days ago · Novo Nordisk is planning a new Phase 3 trial of its next-generation obesity drug CagriSema that will test different doses and longer duration of treatment, the company said Wednesday. The announcement comes six weeks after the Denmark-based company released data from another Phase 3 trial that underperformed executives’ expectations on weight ...

Jun 4, 2021 · Novo Nordisk receives FDA approval for Wegovy™ to treat adults with obesity based on unprecedented efficacy for a prescription medicine in clinical trials - Despite being recognized by leading authorities as a serious disease, obesity remains stigmatized, resulting in patients being underdiagnosed and significantly undertreated

As leaders within the science of obesity, we are working to make obesity a healthcare priority, defeat stigma and support better access to evidence-based care. Adults and children are currently living with obesity globally. The global prevalence of obesity has more than tripled since 1975.

4 days ago · Based on the results, Novo Nordisk is planning further clinical developments for the drug in adults with obesity and overweight. 1. REFERENCES 1. Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity. News release. Novo Nordisk. January 24, 2025.

2 days ago · Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors and wiped $125 billion ...